Pubblicazioni

Autori:

Lombardi, Rosa; Mantovani, Alessandro; Cespiati, Annalisa; Francione, Paolo; Maffi, Gabriele; Del Zanna, Elena; Maffeis, Claudio; Colecchia, Antonio; Passigato, Nicola; Ferrarese, Alberto; Cusumanu, Caterina Daniela; Villani, Rosanna; Orsi, Emanuela; Grancini, Valeria; Airaghi, Lorena; Bignamini, Daniela; Serviddio, Gaetano; Targher, Giovanni; Dongiovanni, Paola; Fargion, Silvia; Fracanzani, Anna Ludovica

Titolo:

Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Digestive Liver Disease

ISSN Rivista:

1590-8658

N° Volume:

56

Editore:

EGI srl

Intervallo pagine:

551-558

Parole chiave:

Fibroscan; Follow-up study; Hepatic steatosis; Liver stiffness measurement; Nonalcoholic fatty liver disease; Prospective; SGLT2 inhibitors; Type 2 diabetes

Breve descrizione dei contenuti:

Background and aims: Patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are at high risk of hepatic fibrosis. To prospectively evaluate changes in fibrosis in diabetic patients with NAFLD, predisposing factors and sodium glucose cotransporter 2 inhibitors (SGLT2i) influence. Methods: 237 T2DM outpatients (mean age 67 ± 9 years, 54% male) were enrolled and re-evaluated after 52 ± 10 months. At baseline and follow-up NAFLD and liver fibrosis (LSM) were detected by ultrasonography and Fibroscan®. Results: During follow-up an increase in LSM (6.0 ± 2.8 vs 5.8 ± 2.7 kPa, p = 0.02) and in the prescription of SGLT2i (20% vs 6%, p<0.001) was registered, despite stability of diabetic control. LSM worsened in 133(56%) subjects, 92 (39%) with worsening >10% from baseline. Patients with worsening versus non worsening of LSM had higher prevalence of increase in BMI during follow-up (45% vs 32%, p = 0.06) and lower SGLT2i prescription (15% vs 27%, p = 0.034). In multivariate analysis use of SGLT2-inhibitors at follow-up reduced the risk of LSM worsening (HR 0.34, 95% CI 0.13-0.88), even when considered>10% from baseline. Conclusions: A high prevalence of fibrosis progression was observed in diabetic subjects with NAFLD over a nearly 5-years follow up and SGLT2-inhibitors seem to reduce the risk of worsening of liver stiffness.

Id prodotto:

137876

Handle IRIS:

11562/1119555

ultima modifica:

10 aprile 2024

Citazione bibliografica:

Lombardi, Rosa; Mantovani, Alessandro; Cespiati, Annalisa; Francione, Paolo; Maffi, Gabriele; Del Zanna, Elena; Maffeis, Claudio; Colecchia, Antonio; Passigato, Nicola; Ferrarese, Alberto; Cusumanu, Caterina Daniela; Villani, Rosanna; Orsi, Emanuela; Grancini, Valeria; Airaghi, Lorena; Bignamini, Daniela; Serviddio, Gaetano; Targher, Giovanni; Dongiovanni, Paola; Fargion, Silvia; Fracanzani, Anna Ludovica, Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors «Digestive Liver Disease» , vol. 56 , 2024 , pp. 551-558

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo